Centaurus Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 22-06-2024
- Paid Up Capital ₹ 0.53 Cr
as on 22-06-2024
- Company Age 21 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.14 Cr
as on 22-06-2024
- Satisfied Charges ₹ 1.87 Cr
as on 22-06-2024
- Revenue 106.12%
(FY 2023)
- Profit 97.76%
(FY 2023)
- Ebitda -12.17%
(FY 2023)
- Net Worth 9.48%
(FY 2023)
- Total Assets 12.77%
(FY 2023)
About Centaurus Pharma
The Corporate was formerly known as Centaurus Pharma Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.53 Cr.
The company currently has active open charges totaling ₹4.14 Cr. The company has closed loans amounting to ₹1.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bharathi Sanikommu and Balachandar Sanikommu serve as directors at the Company.
- CIN/LLPIN
U24239AP2003PTC040650
- Company No.
040650
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Vijayawada, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Centaurus Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharathi Sanikommu  | Director | 30-Dec-2011 | Current |
| Balachandar Sanikommu | Director | 11-Mar-2003 | Current |
Financial Performance and Corporate Structure Insights of Centaurus Pharma.
Centaurus Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 106.12% increase. The company also saw a substantial improvement in profitability, with a 97.76% increase in profit. The company's net worth moved up by a moderate rise of 9.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Centaurus Pharma?
In 2022, Centaurus Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kondapally Envirotech Private Limited
Active 16 years 6 monthsBalachandar Sanikommu is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 24 May 2023 | ₹4.14 Cr | Open |
Sidbi Creation Date: 02 Sep 2020 | ₹3.75 M | Satisfied |
State Bank Of Hyderabad Creation Date: 12 Jan 2007 | ₹1.49 Cr | Satisfied |
How Many Employees Work at Centaurus Pharma?
Unlock and access historical data on people associated with Centaurus Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Centaurus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Centaurus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
